Skip to main content
Terug
Watch Compare

ANAVEX LIFE SCIENCES CORP.

Datakwaliteit: 83%
AVXL
Nasdaq Manufacturing Chemicals
€ 2,95
▼ € 0,10 (-3,28%)
Marktkapitalisatie: 282,19 M
Prijs
€ 3,05
Marktkapitalisatie
282,19 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -34,08 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-36,72%
Boven sectorgemiddelde (-53,47%)
ROIC-29,93%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current RatioN/A
Interest Coverage-10,22

Waardering

PE (TTM)
-7,06
Onder sectorgemiddelde (-1,48)
P/B Ratio2,23
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -7,1 -1,5
P/B 2,2 1,6
ROE % -36,7 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

2 analisten
Buy
Huidig
€ 2,95
+645.8%
Koersdoel
€ 22,00
€ 20,00
€ 22,00
€ 24,00
Vooruitzicht
Forward K/W -21,07
Forward WPA -€ 0,14
Omzet Sch. 36,50 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,14
-€ 0,55 – € 0,27
 36,50 M 2
FY2026 -€ 0,33
-€ 0,33 – -€ 0,32
 388,00 M 2

Winstverassingen

Laatste 5 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,11 -€ 0,06 +45,5%
Q32025 -€ 0,15 -€ 0,11 +26,7%
2026-Q1 -€ 0,08 -€ 0,06 +20,0%
Q22025 -€ 0,15 -€ 0,16 -10,3%
Q12025 -€ 0,15 -€ 0,13 +13,3%

ETFs Holding This Stock

LABU logo LABU Direxion Daily S&P Biotech Bull 3X ETF
0,18% weight
IRSSX IRSSX
0,03% weight
ISCB logo ISCB iShares Morningstar Small-Cap ETF
0,02% weight
GSSC logo GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF
0,02% weight
IIRSX IIRSX
0,01% weight
IRCIX IRCIX
0,01% weight
IRSIX IRSIX
0,01% weight
VVICX VVICX
0,01% weight
WINDX WINDX
0,00% weight
WFIVX WFIVX
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -39,95 M
ROE -36,72% ROA -33,94%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -34,08 M
ROIC -29,93% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage -10,22 Asset Turnover N/A
Working Capital N/A Tangible Book Value 126,62 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -7,06 Forward P/E N/A
P/B Ratio 2,23 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -12,08%
Market Cap 282,19 M Enterprise Value 150,44 M
Per Share
EPS (Diluted TTM) -0,46 Revenue / Share N/A
FCF / Share -0,37 OCF / Share -0,37
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 85,30%
SBC-Adj. FCF -43,01 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -46,38 M -43,00 M -47,51 M -47,98 M -37,91 M
EPS (Diluted) -0,54 -0,52 -0,60 — —
Gross Profit — — — — —
Operating Income -51,41 M -52,88 M -55,76 M -50,99 M —
EBITDA — — — — —
R&D Expenses 37,59 M 41,84 M 43,72 M 37,92 M 32,98 M
SG&A Expenses 13,82 M — — — —
D&A — — — — —
Interest Expense 4,68 M 7,32 M 6,52 M 946.988,0 26.261,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 103,82 M 135,57 M 154,39 M 152,70 M 161,62 M
Total Liabilities 8,95 M 15,30 M 12,53 M 10,21 M 10,80 M
Shareholders' Equity 94,87 M 120,26 M 141,85 M 142,49 M 150,82 M
Total Debt — — — — —
Cash & Equivalents 102,58 M 132,19 M 151,02 M 149,16 M 152,11 M
Current Assets — — — — —
Current Liabilities — — — — —